The biopharmaceutical and biotechnology company Symbiotec Pharmalab is set to tap the capital markets with an initial public offering (IPO) worth Rs 1,757 crore. The company has fixed the price band at Rs 938–Rs 988 per share, with the issue opening for subscription on August 24, 2026, and closing on August 27, 2026.
Investors can bid for a minimum of 15 equity shares, with bids thereafter available in multiples of 15 shares. At the upper end of the price band, the minimum investment will be Rs 14,820.
The IPO is proposed to be listed on both the BSE and NSE, with the tentative listing date scheduled for September 1, 2026. The allotment is likely to be finalised on August 28, 2026.
The company is offering eligible employees a Rs 90-per-share discount on bids made through the employee reservation portion.
Valuation Under the Spotlight
Symbiotec Pharmalab’s IPO valuation is likely to attract close attention from investors. Based on diluted earnings per share for fiscal 2026, the price-to-earnings (P/E) ratio stands at 49.37 times at the lower end of the price band and rises to 52.00 times at the upper end.
The company’s weighted average return on net worth for the last three financial years was 10.99%.
With the IPO price band translating to 469 times the face value at the floor price and 494 times at the cap price, the issue is positioned as a premium offering in the pharmaceutical and biotechnology space.
Where Will the IPO Proceeds Go?
The primary objective of the issue is to strengthen the company’s balance sheet. Symbiotec Pharmalab plans to use the proceeds for prepayment and/or repayment, either fully or partially, of certain outstanding borrowings. The remaining funds will be utilised for general corporate purposes.
Symbiotec Pharmalab
Founded in 2002, Symbiotec Pharmalab operates across the biopharmaceutical and biotechnology space, developing and manufacturing active pharmaceutical ingredients (APIs), nutritional ingredients and specialised products for domestic and international markets.
The company’s journey began with laboratory-scale manufacturing of steroidal-hormone APIs in 1995. Over the years, it has expanded into an industrial-scale, backward-integrated manufacturing platform serving the pharmaceutical, nutraceutical and wellness sectors.
Research-driven manufacturing, quality and sustainability form key elements of its business strategy. Its manufacturing operations have also secured approvals and certifications from several international regulatory bodies, including the US FDA, EU-GMP authorities and South Korea’s Ministry of Food and Drug Safety.
As of June 30, 2025, Symbiotec Pharmalab operated two industrial-scale API manufacturing plants. Together, these facilities had a maximum capacity of 584.67 metric tonnes (MT) for chemical synthesis and 300 kilolitres of fermentation capacity.
The combination of backward integration, specialised API capabilities and international regulatory approvals gives the company an established position in a segment where manufacturing quality and regulatory compliance can be critical differentiators.
IPO Management Team
The IPO is being managed by JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial. MUFG Intime India Pvt. Ltd. is acting as the registrar to the issue.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)